Results 41 to 50 of about 22,234 (251)

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. [PDF]

, 2019
Introduction: Tuberculosis (TB) remains a major health threat and it is now clear that the current vaccine, BCG, is unable to arrest the global TB epidemic. A new vaccine is needed to either replace or boost BCG so that a better level of protection could
Barclay WR, Elena Stylianou, Helen McShane, Matthew J. Paul, Rajko Reljic, Resende Co T, Rodriguez A, Uranga S, Wong EA   +8 more
core   +1 more source

Organization and implementation of an oral cholera vaccination campaign in an endemic urban setting in Dhaka, Bangladesh

Global Health Action, 2019
Bangladesh has historically been cholera endemic, with seasonal cholera outbreaks occurring each year. In collaboration with the government of Bangladesh, the Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (
Iqbal Ansary Khan, Ashraful Islam Khan, Anisur Rahman, Shah Alam Siddique, Md. Taufiqul Islam, Md. Amirul Islam Bhuiyan, Atique Iqbal Chowdhury, Nirod Chandra Saha, Prasanta Kumar Biswas, Amit Saha, Fahima Chowdhury, John D. Clemens, Firdausi Qadri   +12 more
doaj   +1 more source

Controlling Endemic Cholera with Oral Vaccines

PLoS Medicine, 2007
على الرغم من أن التقدم في علاج الإماهة جعل الكوليرا مرضًا يمكن علاجه مع انخفاض معدل الوفيات في الحالات في البيئات التي توفر الرعاية الطبية المناسبة، إلا أن الكوليرا لا تزال تفرض وفيات كبيرة في أكثر سكان العالم فقرًا. تتوفر لقاحات الكوليرا الفموية المعتمدة على الخلايا الكاملة والمرخصة دوليًا (OCVs) منذ أكثر من عقد من الزمان، ولكن لم يتم استخدامها ...
Ira M. Longini, Azhar Nizam, Mohammad Ali, Muhammad Yunus, Neeta Shenvi, John D. Clemens   +5 more
openaire   +4 more sources

PaxVax CVD 103-HgR single-dose live oral cholera vaccine

Expert Review of Vaccines, 2017
Introduction: Cholera remains a problem in developing countries and a risk for travelers. Hypochlorhydria, blood group O, cardiac and renal disease increase the risk of developing cholera gravis.
Myron M. Levine, Wilbur H. Chen, James B. Kaper, Michael Lock, Lisa Danzig, Marc Gurwith   +5 more
doaj   +1 more source

Population-Level Effect of Cholera Vaccine on Displaced Populations, South Sudan, 2014

Emerging Infectious Diseases, 2016
Following mass population displacements in South Sudan, preventive cholera vaccination campaigns were conducted in displaced persons camps before a 2014 cholera outbreak.
Andrew S. Azman, John Rumunu, Abdinasir Abubakar, Haley West, Iza Ciglenecki, Trina Helderman, Joseph Francis Wamala, Olimpia de la Rosa Vázquez, William Perea, David A. Sack, Dominique Legros, Stephen Martin, Justin Lessler, Francisco J. Luquero   +13 more
doaj   +1 more source

Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.

, 2007
Vietnam currently produces an orally administered, bivalent (O1 and O139) killed whole-cell vaccine and is the only country in the world with endemic cholera to use an oral cholera vaccine in public health practice.
Anh, Dang Duc, Attridge, Stephen, Canh, Do Gia, Carbis, Rodney, Clemens, John, Deen, Jacqueline, Han, Seung Hyun, Holmgren, Jan, Long, Phan Thi, Lopez, Anna Lena, Shin, Seong Hye, Son, Nguyen Hong, Thiem, Vu Dinh, von Seidlein, Lorenz   +13 more
core   +1 more source

Oral cholera vaccines and their impact on the global burden of disease

Human Vaccines & Immunotherapeutics, 2019
With one-third of nations at risk of cholera, we can expect to experience massive, rapidly disseminated, and prolonged cholera outbreaks such as those recently experienced in Yemen and Haiti.
Thomas F. Wierzba
doaj   +1 more source

Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study

The Lancet Global Health, 2018
Summary: Background: No study of long-term protection following killed oral cholera vaccination has been done outside of the historically cholera-endemic areas of south Asia, or has examined protection after a single-dose vaccination regimen. To address
Molly F Franke, ScD, Ralph Ternier, MD, J Gregory Jerome, MD, Wilfredo R Matias, MD, Jason B Harris, MD, Louise C Ivers, MD   +5 more
doaj   +1 more source

Effectiveness of one dose of killed oral cholera vaccine in an endemic community in the Democratic Republic of the Congo: a matched case-control study. [PDF]

Lancet Infect Dis
Malembaka EB, Bugeme PM, Hutchins C, Xu H, Hulse JD, Demby MN, Gallandat K, Saidi JM, Rumedeka BB, Itongwa M, Tshiwedi-Tsilabia E, Kitoga F, Bodisa-Matamu T, Kavunga-Membo H, Bengehya J, Kulondwa JC, Debes AK, Taty N, Lee EC, Lunguya O, Lessler J, Leung DT, Cumming O, Okitayemba PW, Mukadi-Bamuleka D, Knee J, Azman AS.   +26 more
europepmc   +3 more sources

Vaccines against toxoplasma gondii : challenges and opportunities [PDF]

, 2009
Development of vaccines against Toxoplasma gondii infection in humans is of high priority, given the high burden of disease in some areas of the world like South America, and the lack of effective drugs with few adverse effects.
Aliberti J, Angus CW, Aosai F, Aosai F, Awan KJ, Beghetto E, Bommireddy R, Bonenfant C, Boyle JP, Brinkmann V, Buxton D, Bülow R, Caetano BC, Conacher M, Cong H, Cong H, Constant SL, Couper KN, Craig W Roberts, Cui YL, Cuppari AF, Curtsinger JM, Curtsinger JM, Cutchins EC, Darcy F, Dautu G, Debard N, Debierre-Grockiego F, DeGregorio E, Denkers EY, Desolme B, Duquesne V, Echeverria PC, Elisabeth Förster-Waldl, Erik Jongert, Escajadillo A, Eskild Petersen, Fachado A, Fachado A, Flori P, Fox B, Frenkel JK, Garcia JL, Garcia JL, Gatkowska J, Gazzinelli R, Gazzinelli RT, Golkar M, Hakim FT, Igarashi M, Innes EA, Ishii K, Ishii KJ, Ismael AB, Ismael AB, Johnson LL, Jongert E, Jongert E, Jongert E, Kasper LH, Khan IA, Kijlstra A, Kodjikian L, Krahenbuhl JL, Kringel H, Letscher-Bru V, Letscher-Bru V, Leyva R, Lindsay DS, Liu Q, Lourenco EV, Lourenço EV, Martin V, McLeod R, Mishima M, Mishima M, Mohamed RM, Mévélec MN, Mévélec MN, Nicola Gargano, Nielsen HV, Nielsen HV, Petersen E, Petrovsky N, Pettersen EK, Pfefferkorn ER, Qu D, Reikvam A, Roque-Resendiz JL, Sabin AB, Sayles PC, Schaap D, Scorza T, Siachoque H, Sibley LD, Silveira C, Stanley AC, Stockinger B, Supply P, Taneja V, Vandepapelierea P, Velge-Roussel F, Velge-Roussel F, Vercammen M, Vogel N, Vyas JM, Waldeland H, Wang H, Wilkins MF, Williams MA, Xue M, Xue M, Yang CD, Yarovinsky F, Zenner L, Zhang G, Zhang J, Zimmermann S   +117 more
core   +3 more sources